Contributed Workshops

Session 1: DM1; UT1; CM1; CM2; MM2; MM4; DA1; DA2; DA3 Session 2: DM2; UT2; CM3; CM4; MM1; MM6; DA4; DA5; DA6 Session 3: DM3; UT3; CM5; CM6; MM3; MM5; MM7; DA7; DA8 27 workshops are presented on Thursday and again on Friday. You have the opportunity to attend 6 of these 27 workshops over the two-day period. You can choose three (3) different workshops on Thursday (one from each of the three sessions given on Thursday), and three (3) workshops on Friday (one for each of the three sessions given on Friday.) Workshop Topics "MODELING METHODOLOGY ISSUES" MM1 MONTE CARLO SIMULATION IN HEALTH CARE MODELS Richter A, Mauskopf JA, Research Triangle Institute, Research Triangle Park, NC, USA MM2 DESIGNING COMPUTER MODELS TO CONVEY COST-EFFECTIVENESS ANALYSES RESULTS Parente ST, Gardner, EN, Mohr, P, Project HOPE Center for Health Affairs, Bethesda, MD, USA MM3 DEVELOPMENT OF DRUG USE PERFORMANCE MODELS AS MEASURES OF PATIENT CARE Holimon TD, Wurtzbacher JD. University of Tennessee College of Pharmacy. Department of Pharmacy Practice and Pharmacoeconomics. Memphis, TN, USA. MM4 RECONCILING DECISION MODELS WITH THE REAL WORLD: THE COST-EFFECTIVENESS OF ERYTHROPOIETIN FOR ESRD-RELATED ANEMIA Kauf T, Shih Y, UNC School of Pharmacy, Chapel Hill, NC, USA MM5 COMPARING COMPUTERIZED OPTIONS IN PHARMACOECONOMICS: SPREADSHEETS, DECISION TREES AND EDUCATIONAL TOOLS: AN OPEN WORKSHOP FOR DEMONSTRATING SOFTWARE McGhan WF. Philadelphia College of Pharmacy and Sciences, Philadelphia, PA. USA MM6 DECISION ANALYSIS: WHAT IS ITS UTILITY FOR PHARMACOECONOMIC ANALYSIS? Caro JJ, Migliaccio-Walle K, Caro Research, Boston, MA, USA MM7 ISSUES IN DEVELOPING ECONOMIC MODELS FOR MANAGED CARE: THE CASE OF OSTEOPOROSIS PREVENTION Funk Orsini P1 , Mullins CD2, Weiss SR2, Preston KL1, 1Parexel Int'l, Alexandria, VA, USA, 2University of Maryland, Baltimore MD, USA "DATA REGISTRIES AND DATA COLLECTION AND USE ISSUES" DA1 USING MEDICATION HISTORY TO MEASURE INDICATION BIAS Leader S, Mallick R. Pracon, Reston VA, USA DA2 THE ROLE OF PATIENT REGISTRIES IN DISEASE MANAGEMENT AND OUTCOMES RESEARCH Hartz SC, Huse DM, Medical Research International, Burlington, MA, USA DA3 USING COMMUNITY PHARMACIES TO CONDUCT OUTCOMES RESEARCH Ungar WJ. Innovus Research Inc, Burlington, Ontario, Canada. DA4 CONSTRUCTION OF A VALIDATED, NORMALIZED, GRANULAR ADMINISTRATIVE DATABASE AND ITS USE IN CLINICAL OUTCOMES IMPROVEMENT, CLINICAL RESEARCH AND PHARMACOECONOMIC RESEARCH Morris S1, Seltzer J2, 1Bryant D, 1Premier, Inc, Charlotte, NC, 2Premier Research Worldwide, Phila., PA, USA DA5 DISEASE STATE MANAGEMENT T RACKER: IMPLEMENTING, TRACKING, AND EVALUATING CLINICAL PATHWAYS AND OUTCOMES. Ambegaonkar AJ, Day D, Main J, Lubowski T, Yamaga C, Van Vleet J, Clinical Pharmacy Outcomes Research, Pfizer Inc, New York, NY, USA DA6 STRATEGIES FOR FORMULARY COMPARISONS IN THE MEDICAID MANAGED CARE ERA Wurtzbacher JD, Holimon TD, University of Tennessee College of Pharmacy, Memphis, TN, USA. DA7 PROSPECTIVE, NATURALISTIC OUTCOMES MEASUREMENT: THE SCHIZOPHRENIA CARE AND ASSESSMENT PROGRAM (SCAP) Haley JC1, Russo PA2, Johnstone BM1, Crown WH2. 1Eli Lilly and Company, Indianapolis, IN, 2The MEDSTAT Group, Washington, DC, USA DA8 EVALUATING HEALTH OUTCOMES AND PHARMACOECONOMIC LITERATURE "ECONOMIC ANALYSIS AND HEALTH CARE DECISIONS ISSUES" DM1 INTERPRETING AND USING COST EFFECTIVENESS RESULTS Bala, MV, Zarkin, GA, Research Triangle Institute, Research Triangle Park, NC, USA DM2 DISSEMINATION OF PHARMACOECONOMIC RESULTS TO MANAGED CARE ORGANIZATIONS Shreve JL, Pedlow KL, Marshall S, VanDenBos J, Milliman & Robertson, Inc., Denver, CO, USA DM3 OUTCOMES RESEARCH IN MEDICATION USE: HCFA'S HEALTH CARE QUALITY IMPROVEMENT PROGRAM Westrick E. Rhode Island Quality Partners, Providence RI, USA. "COSTING METHODOLOGY ISSUES" CM1 ESTIMATING THE COSTS AND OUTCOMES FOR DIFFERENT DISEASE MANAGEMENT STRATEGIES: A CASE STUDY OF CYTOMEGALOVIRUS INFECTION AND DISEASE Mauskopf J1, Annemans L2, Richter A1., Chulay J3; Maclaine G3, 1Research Triangle Institute, RTP, NC; 2HEDM, Belgium; 3Glaxo Wellcome, RTP, NC, USA CM2 CLINICAL INTERVENTION ASSESSMENT: IMPLEMENTATION OF DEFAULT VALUES FOR EXPEDITING THE CALCULATION OF COST SAVINGS AND COST AVOIDANCES Mutnick A. Sterba K. Vrchoticky T. The University of Iowa Hospitals and Clinics, Iowa City, IA, USA CM3 MULTIVARIABLE METHODS FOR MEASURING TREATMENT COSTS IN RANDOMIZED TRIALS Polsky D, Glick H, University of Pennsylvania, Philadelphia, PA., USA CM4 USE OF UB-92S AND MEDICARE COST REPORTS IN LARGE, MULTI-CENTER RANDOMIZED TRIAL: THE PURSUIT EXPERIENCE Davidson-Ray L1, Buell H1, O'Neal B1, McElwee N2, Mark DB1. 1Duke Clinical Research Institute, Durham, NC, USA 2Schering-Plough, Corp., Kenilworth, NJ, USA CM5 DISCOUNTING HEALTH BENEFITS IN PHARMACOECONOMIC ANALYSES: IS IT JUSTIFIED? Caro JJ, Klittich WS, Caro Research, Boston, MA, USA CM6 THE USE OF PATIENT SELF-REPORTS TO COLLECT HEALTH CARE RESOURCE UTILIZATION DATA Crawford B1, Evans C2. 1Charles River Associates, Boston, MA; 2Astra USA, Westborough, MA, USA "UTILITIES METHODOLOGY ISSUES" UT1 TRADE-OFF PREFERENCES FOR PHARMACEUTICAL DEVELOPMENT, MARKETING, AND OUTCOMES EVALUATION Johnson FR, Desvousges WH, Triangle Economic Research, Durham, NC, USA UT2 PRACTICAL APPLICATIONS OF THE HEALTH UTILITIES INDEX Torrance GW1,2, Walker V1, Rosner AJ1.1Innovus Research Inc., Burlington, Ontario, Canada. 2McMaster University, Hamilton, Ontario, Canada. UT3 THE EuroQoL EQ-5D: AN OUTCOME MEASURE FOR USE IN CLINICAL AND ECONOMIC EVALUATION Kind P1, de Charro F2. 1Centre for Health Economics, University of York, England, 2Centre for Health Policy and Law, Erasmus University, Rotterdam, Netherlands